Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
Holding ENTA?
Track your performance easily
ENTA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.51 - $17.80
Previous Close$9.01
Volume268.52K
Average Volume (3M)165.41K
Market Cap
$176.92M
Enterprise Value$11.39M
Total Cash (Recent Filing)$230.09M
Total Debt (Recent Filing)$50.57M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Feb 05, 2025EPS Estimate
-$1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.49
Shares Outstanding21,188,571
10 Day Avg. Volume115,117
30 Day Avg. Volume165,409
Standard Deviation0.16
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.29
Price to Sales (P/S)2.77
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.16
Enterprise Value/Gross Profit0.14
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$22.67Price Target Upside171.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Enanta Pharmaceuticals News
PremiumCompany Announcements
Enanta Pharmaceuticals Reports Q4 2024 Financials
Bulls Say, Bears Say
Bulls Say
Analyst ConfidenceAnalyst reiterates a Market Outperform rating for Enanta Pharmaceuticals, reflecting confidence in the company's prospects.
Competitive AdvantageThe discontinuation of Pfizer's fusion inhibitor sisunatovir for business reasons could benefit Enanta Pharmaceuticals if its candidates succeed.
Product DevelopmentEDP-323's anti-viral capability validated by this challenge study is seen as a crucial milestone for Enanta.
Bears Say
Clinical Trial HesitationHesitation regarding zelicapavir exists due to its failure in a previous field trial in healthy adults, despite strong challenge trial results.
Clinical TrialsClinical trial failures of planned and ongoing studies pose significant risks to the investment thesis and target price.
Regulatory ApprovalFailure to secure regulatory approval of EDP-938, EDP-323, or EDP-514 could negatively impact the company.
---
Ownership Overview
7.02% Insiders
13.69% Mutual Funds
31.93% Other Institutional Investors
36.45% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENTA FAQ
What was Enanta Pharmaceuticals’s price range in the past 12 months?
Enanta Pharmaceuticals lowest stock price was $8.51 and its highest was $17.80 in the past 12 months.
What is Enanta Pharmaceuticals’s market cap?
Currently, no data Available
When is Enanta Pharmaceuticals’s upcoming earnings report date?
Enanta Pharmaceuticals’s upcoming earnings report date is Feb 05, 2025 which is in 71 days.
How were Enanta Pharmaceuticals’s earnings last quarter?
Enanta Pharmaceuticals released its earnings results on Nov 25, 2024. The company reported -$1.36 earnings per share for the quarter, missing the consensus estimate of -$1.161 by -$0.199.
Is Enanta Pharmaceuticals overvalued?
According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
Does Enanta Pharmaceuticals pay dividends?
Enanta Pharmaceuticals does not currently pay dividends.
What is Enanta Pharmaceuticals’s EPS estimate?
Enanta Pharmaceuticals’s EPS estimate is -$1.25.
How many shares outstanding does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 21,188,572 shares outstanding.
What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
Enanta Pharmaceuticals reported an EPS of -$1.36 in its last earnings report, missing expectations of -$1.161. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
Among the largest hedge funds holding Enanta Pharmaceuticals’s share is Farallon Capital Management, L.L.C.. It holds Enanta Pharmaceuticals’s shares valued at 22M.
---
Enanta Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.67 (171.50% Upside)
$22.67 (171.50% Upside)
Hedge Fund Trend
Increased
By 13.3K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.35%
12-Months-Change
Fundamentals
Return on Equity
-67.17%
Trailing 12-Months
Asset Growth
-19.83%
Trailing 12-Months
Company Description
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
---
ENTA Company Deck
---
ENTA Earnings Call
Q2 2024
0:00 / 0:00
---
ENTA Stock 12 Month Forecast
Average Price Target
$22.67
▲(171.50% Upside)
Technical Analysis
Best Analysts Covering ENTA
1 Year
1 Year Success Rate
8/18 ratings generated profit
1 Year Average Return
+5.22%
assigned a buy rating 4 months ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +5.22% per trade.
---